Commentary Open Access
Volume 2 | Issue 4 | DOI: https://doi.org/10.33696/diabetes.1.028
Can Monoclonal Antibodies against CGRP Offer New Treatment Options for Type 2 Diabetes?
Celine E Riera1,2,*
- 1Center for Neural Science and Medicine, Department of Biomedical Sciences, Board of Governors Regenerative Medicine Institute, Department of Neurology, Cedars-Sinai Medical Center, 127 South San Vicente Boulevard, Los Angeles CA 90048, USA
- 2David Geffen School of Medicine, University of California, Los Angeles, USA
Corresponding Author
Celine E Riera, Celine.riera@cshs.org
Received Date: November 20, 2020
Accepted Date: December 29, 2020
Citation:
Riera CE. Can Monoclonal Antibodies against CGRP Offer New Treatment Options for Type 2 Diabetes?. J Diabetes Clin Res. 2020; 2(4):114-118.
Copyright: © 2020 Riera CE. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.